Cellebrite DI Ltd. (NASDAQ:CLBT) Receives $23.43 Consensus Target Price from Analysts

Shares of Cellebrite DI Ltd. (NASDAQ:CLBT) have earned an average recommendation of “Buy” from the seven research firms that are covering the stock, MarketBeat.com reports. Seven research analysts have rated the stock with a buy rating. The average 12-month target price among brokers that have issued a report on the stock in the last year is $23.43.

A number of equities research analysts recently issued reports on CLBT shares. Needham & Company LLC reissued a “buy” rating and issued a $28.00 price target on shares of Cellebrite DI in a research note on Thursday. JPMorgan Chase & Co. lifted their target price on shares of Cellebrite DI from $24.00 to $28.00 and gave the company an “overweight” rating in a research report on Tuesday, February 11th. Finally, Lake Street Capital boosted their target price on shares of Cellebrite DI from $17.00 to $26.00 and gave the stock a “buy” rating in a research note on Friday, February 14th.

Cellebrite DI Stock Performance

Shares of Cellebrite DI stock opened at $19.61 on Friday. Cellebrite DI has a fifty-two week low of $10.25 and a fifty-two week high of $26.30. The company has a market cap of $4.70 billion, a P/E ratio of -14.11, a price-to-earnings-growth ratio of 4.27 and a beta of 1.52. The firm has a 50-day simple moving average of $20.92 and a two-hundred day simple moving average of $19.85.

Cellebrite DI (NASDAQ:CLBT) last issued its quarterly earnings results on Thursday, February 13th. The company reported $0.07 earnings per share (EPS) for the quarter, missing analysts’ consensus estimates of $0.10 by ($0.03). Cellebrite DI had a positive return on equity of 58.70% and a negative net margin of 70.54%. Equities research analysts forecast that Cellebrite DI will post 0.3 EPS for the current year.

Hedge Funds Weigh In On Cellebrite DI

Hedge funds and other institutional investors have recently modified their holdings of the business. Quarry LP acquired a new stake in Cellebrite DI in the 3rd quarter valued at about $27,000. Advisors Asset Management Inc. grew its position in shares of Cellebrite DI by 130.5% in the third quarter. Advisors Asset Management Inc. now owns 3,077 shares of the company’s stock valued at $52,000 after purchasing an additional 1,742 shares in the last quarter. Gen Wealth Partners Inc acquired a new stake in shares of Cellebrite DI in the fourth quarter valued at approximately $85,000. NewEdge Advisors LLC lifted its position in Cellebrite DI by 600.7% during the fourth quarter. NewEdge Advisors LLC now owns 3,910 shares of the company’s stock worth $86,000 after buying an additional 3,352 shares in the last quarter. Finally, R Squared Ltd acquired a new position in Cellebrite DI during the fourth quarter worth $100,000. 45.88% of the stock is owned by hedge funds and other institutional investors.

Cellebrite DI Company Profile

Cellebrite DI Ltd. develops solutions for legally sanctioned investigations in Europe, the Middle East, Africa, the Americas, and the Asia-Pacific. The company's DI suite of solutions allows users to collect, review, analyze, and manage digital data across the investigative lifecycle with respect to legally sanctioned investigations used in various cases, including child exploitation, homicide, anti-terror, border control, sexual crimes, human trafficking, corporate security, cryptocurrency, and intellectual property theft.